Eli Wallace
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
-
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- DNA Repair Mechanisms
Papers in
-
- Melanoma and MAPK Pathways 4
- DNA Repair Mechanisms 2
- Oncology 6
- HER2/EGFR in Cancer Research 3
- Colorectal Cancer Treatments and Studies 2
- Co-authors
- Kevin M. Koch (6 shared papers)Tammie C. Yeh (3 shared papers)Stefan Groß (6 shared papers)James D. Winkler (3 shared papers)Patrice A. Lee (2 shared papers)Vivienne Marsh (2 shared papers)Brian Hurley (2 shared papers)Joe Lyssikatos (4 shared papers)
- Journals
- Cancer Research (5 papers)Molecular Cancer Therapeutics (2 papers)Clinical Cancer Research (1 paper)Current Topics in Medicinal Chemistry (1 paper)Cancer Biology & Therapy (1 paper)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Eli Wallace
15 papers receiving 679 citations
Peers
Comparison fields: 5 of 61
- Oncology 296
- Molecular Biology 538
- Pathology and Forensic Medicine 111
- Cancer Research 67
- Cell Biology 66
Countries citing papers authored by Eli Wallace
This map shows the geographic impact of Eli Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Wallace more than expected).
Fields of papers citing papers by Eli Wallace
This network shows the impact of papers produced by Eli Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Wallace. The network helps show where Eli Wallace may publish in the future.
Co-authors
The 25 scholars most cited alongside Eli Wallace, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 442 | |
| 2 | 2011 | 67 | |
| 3 | 2005 | 56 | |
| 4 | 2010 | 28 | |
| 5 | 2011 | 22 | |
| 6 | Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2. | 2009 | 20 |
| 7 | 1964 | 12 | |
| 8 | 2024 | 11 | |
| 9 | ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors | 2007 | 9 |
| 10 | 2021 | 8 | |
| 11 | 1998 | 8 | |
| 12 | 2016 | 5 | |
| 13 | 2016 | 5 | |
| 14 | 2011 | 3 | |
| 15 | 2006 | 1 | |
| 16 | Differential activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 compared to lapatanib in in vivo xenograft models | 2008 | 0 |
About Eli Wallace
Eli Wallace is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cell Biology and Organic Chemistry, having authored 16 papers that have together received 697 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (4 papers), Microtubule and mitosis dynamics (4 papers), Cancer, Hypoxia, and Metabolism (3 papers), HER2/EGFR in Cancer Research (3 papers), Colorectal Cancer Treatments and Studies (2 papers), Lung Cancer Treatments and Mutations (2 papers), DNA Repair Mechanisms (2 papers) and Synthesis and biological activity (2 papers). The work is most often cited by research in Oncology (296 citations), Molecular Biology (538 citations), Pathology and Forensic Medicine (111 citations), Cancer Research (67 citations) and Cell Biology (66 citations). Eli Wallace has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Kevin M. Koch, Tammie C. Yeh, Stefan Groß, James D. Winkler, Patrice A. Lee, Vivienne Marsh, Brian Hurley, Joe Lyssikatos, Allison Marlow and R J Evans. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Current Topics in Medicinal Chemistry and Cancer Biology & Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.